Skip to content
Research/Peptides/CJC-1295 No DAC (Modified GRF 1-29)

CJC-1295 No DAC (Modified GRF 1-29)

Mod GRF 1-29, CJC No DAC. Short-acting GHRH analog without DAC modification. Creates a high, pulsatile GH release, more natural GH stimulation. Combined with Ipamorelin for synergistic effects.

Intelligence Profile

Safety Profile

Critical Evidence Limitation: No clinical trials or peer-reviewed studies were retrieved for CJC-1295 No DAC (Modified GRF 1-29). The safety profile of this compound has not been established through rigorous scientific research.

Known Side Effects

Due to the absence of clinical trial data, the side effect profile of CJC-1295 No DAC is unknown. Without controlled studies, it is impossible to determine the frequency, severity, or nature of potential adverse reactions.

Contraindications

No evidence-based contraindications have been established for CJC-1295 No DAC. The lack of safety data means potential contraindications remain unidentified.

Drug Interactions

No drug interactions have been studied or documented for CJC-1295 No DAC. The potential for interactions with medications, supplements, or other compounds is unknown.

High-Risk Populations

Without safety studies, it is unclear which populations should avoid CJC-1295 No DAC. Standard precautions would suggest avoiding use in:

  • Pregnant or breastfeeding women
  • Children and adolescents
  • Individuals with underlying medical conditions
  • Those taking medications

However, these recommendations are based on general safety principles rather than specific evidence for this compound.

Important Safety Disclaimer

The absence of published safety data represents a significant concern. This compound has not undergone the rigorous testing required to establish its safety profile. Anyone considering its use should consult with a healthcare provider and be aware that the risks are unknown and potentially serious.

This information is for educational purposes only and does not constitute medical advice. Consult a healthcare professional before considering any therapeutic compound.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.